Skip to main content
TipRanks
Go Ultimate75% OFF

Travere Therapeutics (TVTX) Stock Price & Analysis

636 Followers

TVTX Stock Chart & Stats

$47.00-$1.30(-2.69%)
At close: 4:00 PM EST
$50$55$60$65Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
$46.90 - $49.35
52-Week Range
$22.59 - $68.73
Previous Close
$48.30
Volume
N/A
Average Volume (3M)
2.00M
Market Cap
$4.51B
Enterprise Value
$5.72B
Total Cash (Recent Filing)
$471.82M
Total Debt (Recent Filing)
$616.15M
Price to Earnings (P/E)
―
Beta
1.57
Next Earnings
Feb 25, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Revenue Growth And Product Economics

Rapid revenue expansion combined with exceptionally high gross margins indicates strong product economics and growing commercial adoption. If FILSPARI demand continues scaling across its indications, the company can build greater operating leverage and generate substantial resources to support future pipeline investment.

FILSPARI Commercial Traction

Record quarterly sales, strong conversion to paid therapy, and high adherence across IgA nephropathy and FSGS support a durable commercial foundation. Low switching and expanding prescriber adoption suggest FILSPARI may retain patients while continuing to penetrate underdiagnosed and newly launched segments.

Cash Generation And Pipeline Funding

The recent shift to positive operating and free cash flow improves Travere’s ability to fund commercial expansion and clinical development internally. Combined with reported cash and securities, this provides meaningful resources to advance the pipeline while reducing immediate reliance on additional external financing.

Bears Say

High Leverage And Thin Equity

Sharp debt growth alongside substantial equity erosion leaves Travere with a very thin capital cushion. This high leverage can constrain strategic flexibility, increase the importance of sustained FILSPARI cash generation, and make the company more vulnerable if operating performance or pipeline execution weakens.

Persistent And Worsening Losses

Despite strong revenue and gross margins, Travere has not yet translated commercial growth into consistent operating profitability. The deterioration in TTM EBITDA and net income indicates that operating costs, launch investment, and development spending remain substantial, potentially limiting retained cash and earnings visibility.

Chief Executive Transition

A CEO change during rapid commercialization and pipeline advancement introduces execution and continuity risk over the coming quarters. The incoming leader’s transition must preserve FILSPARI momentum, manage elevated investment, and maintain development priorities while stakeholders adapt to new strategic leadership.

Travere Therapeutics News

TVTX FAQ

What was Travere Therapeutics’s price range in the past 12 months?
Travere Therapeutics lowest stock price was $22.59 and its highest was $68.73 in the past 12 months.
What is Travere Therapeutics’s market cap?
Travere Therapeutics’s market cap is $4.51B.
When is Travere Therapeutics’s upcoming earnings report date?
Travere Therapeutics’s next earnings report is estimated for Feb 25, 2027 (not yet confirmed), which is in 95 days.
How were Travere Therapeutics’s earnings last quarter?
Travere Therapeutics released its earnings results on Nov 02, 2026. The company reported -$0.55 earnings per share for the quarter, missing the consensus estimate of -$0.055 by -$0.495.
Is Travere Therapeutics overvalued?
According to Wall Street analysts Travere Therapeutics’s price is currently Undervalued.
Does Travere Therapeutics pay dividends?
Travere Therapeutics does not currently pay dividends.
What is Travere Therapeutics’s EPS estimate?
Travere Therapeutics’s EPS estimate is 0.44.
How many shares outstanding does Travere Therapeutics have?
Travere Therapeutics has 95,992,160 shares outstanding.
What happened to Travere Therapeutics’s price movement after its last earnings report?
Travere Therapeutics reported an EPS of -$0.55 in its last earnings report, missing expectations of -$0.055. Following the earnings report the stock price went up 0.305%.
Which hedge fund is a major shareholder of Travere Therapeutics?
Hedge funds hold Travere Therapeutics shares: the largest hedge-fund position in Travere Therapeutics is 72,326,609 shares, and hedge funds increased their holdings by 387.2K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology